2/28/2024

Lidocaine Hydrochloride Oral Topical Solution (Viscous) 2%

Products Affected - Description

- Viscous Lidocaine oral solution, Akorn, 2%, 100 mL bottle, 1 count, NDC 50383-0775-04 - discontinued
- Viscous Lidocaine oral solution, Akorn, 2%, 15 mL unit-dose cup 40 count, NDC 50383-0775-17 - discontinued
- Viscous Lidocaine oral solution, Hikma, 2%, 100 mL bottle, 1 count, NDC 00054-3500-49
- Viscous Lidocaine oral solution, Wockhardt USA, 2%, 100 mL bottle, 1 count, NDC 64679-0464-00 - discontinued

Reason for the Shortage

- Akorn ceased operations in February 2023.
- Chartwell launched viscous lidocaine oral solution in late-2023.
- Hikma did not provide a reason for the shortage.
- Morton Grove Pharmaceutical stopped production at its plant in Morton Grove, IL. Lidocaine 2% viscous oral topical solution was transitioned to Wockhardt.
- Wockhardt has discontinued lidocaine 2% viscous oral topical solution and the company has plans to relaunch the product in late-2024.

Available Products

- Viscous Lidocaine oral solution, Chartwell, 2%, 100 mL bottle, 1 count, NDC 62135-0712-42

Estimated Resupply Dates

- Hikma has viscous lidocaine 2% in 100 mL bottles on allocation.

Updated

Updated February 28, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created April 12, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.